Tenderwize
Retour à la recherche

Non-exclusive pharmaceutical discount agreement for Urapidil

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Mar 31, 2028 · 581 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Urapidil (ATC-Code nach WHO: C02CA06)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No minimum purchase quantities; actual revenue uncertain and may be zero.

Buyer can terminate the Open-House process if exclusive agreements are signed, leading to termination of existing non-e...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Non-exclusive discount agreements for Urapidil (ATC C02CA06) under § 130a Abs. 8 SGB V
  • Supply of pharmaceutical products to AOK PLUS for patients in Saxony and Thuringia
Afficher le résumé complet

This notice announces a non-exclusive drug discount agreement (Rabattvereinbarung) for the active substance Urapidil (ATC C02CA06) under an Open-House model. The contracting authority is AOK PLUS for Saxony and Thuringia. No minimum volumes are guaranteed, and quantities depend on demand. The agreement runs until 31 March 2028, with possible early termination if exclusive agreements are concluded. Submission is via the DTVP portal, with a confidentiality requirement. No tender value is published.

Risques

No minimum purchase quantities; actual revenue uncertain and may be zero.

Buyer can terminate the Open-House process if exclusive agreements are signed, leading to termination of existing non-e...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG

Administrative

  • Confidentiality: absolute silence on the content of participation documents
  • Electronic submission via DTVP portal after access request

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

Not applicable - Open-House model without award criteria.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive pharmaceutical discount agreement for Urapidil

Non-exclusive framework agreement for Urapidil under an Open-House model. No exclusivity, negotiations, or minimum quantities. All eligible pharmaceutical entrepreneurs may join.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Mar 2026 - Mar 2028

Catégorie

Pharmaceutical products

Critères d'attribution

Not applicable - Open-House model without award criteria.

Date limite

Deadline Mar 31, 2028

Détails de la procédure

Date de publication
25 Jan 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
56028-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30